Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells 9,787 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 9,787 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $26.20, for a total value of $256,419.40. Following the completion of the transaction, the executive vice president owned 138,043 shares of the company’s stock, valued at approximately $3,616,726.60. This trade represents a 6.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Amphastar Pharmaceuticals Trading Up 1.6%

NASDAQ:AMPH traded up $0.43 during midday trading on Thursday, hitting $26.50. 338,640 shares of the company traded hands, compared to its average volume of 525,798. The company has a current ratio of 3.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.78. The firm’s fifty day moving average is $25.52 and its 200-day moving average is $25.67. The firm has a market capitalization of $1.22 billion, a P/E ratio of 11.73, a P/E/G ratio of 7.18 and a beta of 0.91. Amphastar Pharmaceuticals, Inc. has a 12-month low of $20.39 and a 12-month high of $40.74.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.10. The business had revenue of $191.84 million for the quarter, compared to analysts’ expectations of $186.90 million. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. On average, sell-side analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current year.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in AMPH. Farther Finance Advisors LLC increased its stake in shares of Amphastar Pharmaceuticals by 356.0% during the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock valued at $25,000 after buying an additional 737 shares during the period. FNY Investment Advisers LLC bought a new position in Amphastar Pharmaceuticals during the 3rd quarter worth about $26,000. Global Retirement Partners LLC increased its position in Amphastar Pharmaceuticals by 219.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock valued at $27,000 after purchasing an additional 703 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Amphastar Pharmaceuticals by 192.8% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company’s stock valued at $29,000 after purchasing an additional 831 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 3,430.8% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock valued at $32,000 after purchasing an additional 1,338 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

AMPH has been the subject of several analyst reports. Needham & Company LLC decreased their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a research note on Monday, December 8th. Barclays began coverage on Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price objective on the stock. Bank of America increased their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Finally, Zacks Research lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 14th. Two equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $31.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.